Symphony Health and dentsu health partner to efficiently reach rare disease patients
dentsu health partnered with Symphony Health to improve targeting efficiency for rare-disease marketing campaigns. The collaboration used Symphony Health's custom audiences and an Audience Quality Index to measure diagnosed-patient reach relative to disease prevalence, finding that "standalone reach rates can be misleading" for rare-disease populations. Symphony Health's claims modeling helped identify higher-performing audience segments, letting dentsu health increase diagnosed-patient reach while maintaining cost efficiency, using a consistent Test & Learn framework to compare data partners and optimize delivery. No specific numerical outcomes are given in the visible content.
HealthVerity is a real-world-data marketplace aggregating claims, EHR and lab data from 75+ sources via a proprietary patient-matching layer.
This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.
Published by HealthVerity on its own site — read the original case study on info.healthverity.com ↗
Related use cases
- 01Differentiating TYK2 inhibitors with real-world evidence in psoriasis
- 02How HealthVerity Audiences delivered 26.9x targeting precision for a rare kidney disease campaign
- 03Reducing targeting noise by supplementing claims with oncology labs: Metastatic breast cancer case study
- 04Accurately targeting chronic liver disease patients for specialty therapy
- 05Accurately reaching patients with rare hematologic disease
- 06Accelerating early RWE exploration without increasing analytic burden